NO20060190L - <n-pyrrolidin-3-ylamide derivatives as serotonin and norepinephrine reuptake inhibitors - Google Patents

<n-pyrrolidin-3-ylamide derivatives as serotonin and norepinephrine reuptake inhibitors

Info

Publication number
NO20060190L
NO20060190L NO20060190A NO20060190A NO20060190L NO 20060190 L NO20060190 L NO 20060190L NO 20060190 A NO20060190 A NO 20060190A NO 20060190 A NO20060190 A NO 20060190A NO 20060190 L NO20060190 L NO 20060190L
Authority
NO
Norway
Prior art keywords
alkyl
alkoxy
aryl
het
cycloalkyl
Prior art date
Application number
NO20060190A
Other languages
Norwegian (no)
Inventor
Alan Stobie
Michael Jonathan Fray
Paul Vincent Fish
Gavin Alistair Whitlock
Deborah Jane Lovering
Florian Wakenhut
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27636730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060190(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2004/001943 external-priority patent/WO2004110995A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20060190L publication Critical patent/NO20060190L/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Forbindelse med formel (I) og farmasøytisk og/eller veterinærakseptable derivater derav, hvori R' er H, Ci-ealkyl, -C(X)Y, C3.«cykloalkyl, atyl, het, atyl-Ci.4alkyl, eller het-Ci.4alkyl, hvori cykloalkyl, aryl eller hetgmppene er eventuelt substituert med minst en substituent uavhengig valgt fra Ci.8allyl, Ci.8alkoksy, OH, halo, CF3, OCF3, SCF3, hydroksy-Ci.6alkyl, Ci-4alkoksy-Ci.6alkyl og Ci.4alkyl-S-Ci.4alkyl; R^ er atyl eller heteroaryl, hver eventuelt substituert med minst en subtituent uavhengig valgt fra Ci.galkyl, Ci.galkoksy, OH, halo, CF3, OCF3, SCF3, hydroksy-Ci-ealkyl, Ci.4.alkoksy-Ci.6alkyl og Ci.4alkyl-S-Ci.4alkyl; R^ er Ci-ealkyl, C3.8cykloalkyl,C3-8cykloalkyl-Ci.6alkyl, aryl, het, aiyl-Ci.4alkyl, eller het-Ci.4alkyl, hvori cykloalkyl, aryl eller hetgmppene er eventuelt substituert med minst en substituent uavhengig valgt fra Ci-ealkyl, Cuealkoksy, OH, halo, CF3, OCF3, SCF3, hydroksy-Ci.6alkyl,C i.4alkoksy-Ci.6alkyl og Ci.4alkyl-S-Ci.4alkyl; X er S eller O; Y er H, Ci.6alkyl, Ci.6alkoksy, aryl, het, aryl-Ci.4alkyl eller het-Ci.4alkyl; n er 1 eller 2, fomtsatt at når n er 1, er m 0 eller 2 og n er 2, er m 0, hvori hvis m er 0, da representerer * et kiralt senter. Forbindelsene ifølge oppfinnelsen fremviser aktivitet som både serotonin og noradrenalingjenopptagningsinhibitorer og har derfor anvendelse innenfor et antall terapeutiske områder, for eksempel urininkontinens.A compound of formula (I) and pharmaceutically and / or veterinarily acceptable derivatives thereof wherein R 1 is H, C 1-6 alkyl, -C (X) Y, C 3-6 cycloalkyl, atyl, het, atyl-C 1-4 alkyl, or hetero- C 1-4 alkyl, wherein the cycloalkyl, aryl or het group is optionally substituted with at least one substituent independently selected from C 1-8 allyl, C 1-8 alkoxy, OH, halo, CF 3, OCF 3, SCF 3, hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1. 6alkyl and C1-4alkyl-S-C1-4alkyl; R 1 is atyl or heteroaryl, each optionally substituted with at least one subtituent independently selected from C 1-6 alkyl, C 1-4 alkoxy, OH, halo, CF 3, OCF 3, SCF 3, hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl and C 1-4 alkyl-S-C 1-4 alkyl; R 1 is C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl C 1-6 alkyl, aryl, het, aryl-C 1-4 alkyl, or het-C 1-4 alkyl, wherein the cycloalkyl, aryl or hete groups are optionally substituted with at least one substituent independently selected from C 1-6 alkyl, Cualkoxy, OH, halo, CF 3, OCF 3, SCF 3, hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl and C 1-4 alkyl-S-C 1-4 alkyl; X is S or O; Y is H, C 1-6 alkyl, C 1-6 alkoxy, aryl, het, aryl-C 1-4 alkyl or het-C 1-4 alkyl; n is 1 or 2, assuming that when n is 1, m is 0 or 2 and n is 2, m is 0, wherein if m is 0, then * represents a chiral center. The compounds of the invention exhibit activity as both serotonin and norepinephrine reuptake inhibitors and therefore have utility in a number of therapeutic areas, for example urinary incontinence.

NO20060190A 2003-06-17 2006-01-12 <n-pyrrolidin-3-ylamide derivatives as serotonin and norepinephrine reuptake inhibitors NO20060190L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314048.0A GB0314048D0 (en) 2003-06-17 2003-06-17 Novel compounds
PCT/IB2004/001943 WO2004110995A1 (en) 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors

Publications (1)

Publication Number Publication Date
NO20060190L true NO20060190L (en) 2006-01-12

Family

ID=27636730

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060190A NO20060190L (en) 2003-06-17 2006-01-12 <n-pyrrolidin-3-ylamide derivatives as serotonin and norepinephrine reuptake inhibitors

Country Status (9)

Country Link
CN (1) CN1835921A (en)
GB (1) GB0314048D0 (en)
GT (1) GT200400121A (en)
NO (1) NO20060190L (en)
OA (1) OA13178A (en)
RS (1) RS20050924A (en)
TN (1) TNSN05321A1 (en)
UA (1) UA80338C2 (en)
ZA (1) ZA200509132B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008339351B2 (en) * 2007-12-19 2013-02-28 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic heterocyclic derivative

Also Published As

Publication number Publication date
OA13178A (en) 2006-12-13
UA80338C2 (en) 2007-09-10
RS20050924A (en) 2008-04-04
TNSN05321A1 (en) 2007-07-10
GB0314048D0 (en) 2003-07-23
CN1835921A (en) 2006-09-20
GT200400121A (en) 2005-03-03
ZA200509132B (en) 2007-02-28

Similar Documents

Publication Publication Date Title
NO20055204L (en) Derivatives of piperidinyl and pipemzinylalkylcarbamates, processes for their preparation and use of the same in therapy
NO20055688L (en) Organic compounds
NO20074093L (en) Methods for Preparing Glucopyranosyl-Substituted Benzyl-Benzene Derivatives and Intermediates
MX2012008372A (en) Cycloalkyl-substituted imidazole derivative.
TW200635585A (en) Monocyclic substituted methanones
EP1679069A4 (en) NEW PIPERIDINE DERIVATIVE
MY152008A (en) Pyrrole compounds
NO20055568L (en) Substituted 1,4-diazepines and uses thereof
NO20083598L (en) Carbocyclic and heterocyclic arylsulfones as inhibitors of gamma secretase
WO2005037785A3 (en) Derivatives of n-[phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics
BR112012032813A2 (en) compound, pharmaceutical composition, and method for preventing, treating or ameliorating a disease or condition.
WO2007011820A3 (en) Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
MXPA05013960A (en) N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors.
NO20072409L (en) Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds
WO2006086705B1 (en) Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists
ATE428422T1 (en) PIPERIDINE DERIVATIVES AS CCR3 ANTAGONISTS
NO20045701L (en) Piperidine derivative, its preparation and use
NO20060206L (en) New azetidine compounds
WO2009118473A3 (en) Azetidine-derived compounds, preparation method therefor and therapeutic use of same
CY1111748T1 (en) 7-ALKYNYL-1.8-NAPHYTYRIDONES PRODUCTION, THEIR PREPARATION AND THEIR APPLICATION TO THERAPEUTICS
RU2009142997A (en) 4-ALCOXYPYRIDAZINE DERIVATIVES AS FAST DISSOCIOUS DOPAMINE RECEPTOR 2 ANTAGONISTS
DK2125736T3 (en) Substituted acetophenones suitable as PDE4 inhibitors
BRPI0409002A (en) 1,3,4-substituted pyrazoles for use as 5h-t receptor antagonists in the treatment of psychosis and neurological disorders
BRPI0411603A (en) 4- (Aminomethyl) piperidine benzamides as antagonists 5ht4
CY1115635T1 (en) 2-PYRIDIN-2-YLO-PYRAZOL-3 (2H) -ONE PRODUCT, ITS PREPARATION AND ITS APPLICATION TO THERAPEUTICS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application